Abstracts tagged "radiography and rheumatoid arthritis (RA)"

Abstract Number: 1450 • 2018 ACR/ARHP Annual Meeting
Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy
Kevin R. Lammert¹, Alan R. Erickson², Brian C. Sauer¹ and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatologists rely on hand radiograph findings including bone erosions (BE) and joint space narrowing (JSN) to make treatment decisions for patients with rheumatoid arthritis…
Abstract Number: 1454 • 2018 ACR/ARHP Annual Meeting
Levels of 14-3-3eta Are an Independent Predictor of Long-Term Radiographic Erosive Progression and of Short-Term Rapid Radiographic Erosive Progression in Patients with Inflammatory Polyarthritis
Gilles Boire¹, Nathalie Carrier², Artur J deBrum Fernandes³, Patrick Liang¹, Ariel Masetto⁴, Sophie Roux⁴, Norma K Biln⁵, Yuan Gui⁵, Jane Savill⁵, Sara Michienzi⁵ and Walter P. Maksymowych⁶, ¹Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ³Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Augurex Life Sciences Corp, Vancouver, BC, Canada, ⁶Department of Medicine, CaRE Arthritis and University of Alberta, Edmonton, Canada, Edmonton, AB, Canada
Background/Purpose: Our objective is to examine the additional contribution of 14-3-3η levels to known predictors of radiographic progression in inflammatory polyarthritis, both over several years…
Abstract Number: 1455 • 2018 ACR/ARHP Annual Meeting
Development of a Predictive Model of Radiological Damage in Patients with Rheumatoid Arthritis Based on Artificial Intelligence
Jose M Lezcano¹, José Ivorra-Cortes², Alfredo Madrid³, Raquel Lopez-Mejías⁴, Javier Martin⁵, Benjamín Fernández-Gutiérrez⁶, Miguel Angel González-Gay⁷, Alejandro Balsa⁸, Isidoro Gonzalez-Alvaro⁹, Fernando Salazar¹⁰, Lydia A Alcazar¹¹ and Luis Rodriguez-Rodriguez¹¹, ¹Helix BioS CEO, Madrid, Spain, ²Rheumatology, University Hospital la Fe, Valencia, Spain, ³Rheumatology Department, and Instituto de Investigación Sanitaria (IdISSC), Hospital Clínico San Carlos, Madrid, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁵Instituto de Parasitología y Biomedicina López Neyra, Granada, Spain, ⁶Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ⁷School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ⁸Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁹Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ¹⁰International Centre for Numerical Methods in Engineering (CIMNE), Madrid, Spain, ¹¹Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with increased mortality and disability. Although different factors have been associated with prognosis, it is…
Abstract Number: 559 • 2018 ACR/ARHP Annual Meeting
Radiographic Progression Based on Baseline Demographics and Disease Characteristics from Three TNF-Alpha Inhibitor Biosimilar Studies in Patients with Rheumatoid Arthritis
Josef S. Smolen¹, Young Mo Kang², Wan-Hee Yoo³, Paul Emery⁴, Michael E Weinblatt⁵, Edward C. Keystone⁶, Mark C. Genovese⁷, Gihyun Myung⁸, Evelyn Hong⁸, Inyoung Baek⁸ and Jeehoon Ghil⁸, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Chonbuk National University School of Medicine, Jeonju, Korea, Republic of (South), ⁴University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷Stanford University Medical Center, Palo Alto, CA, ⁸Samsung Bioepis Co., Ltd., Incheon, Korea, Republic of (South)
Background/Purpose: SB4, SB2, and SB5 are biosimilars of reference etanercept, infliximab, and adalimumab, respectively. Radiographic data were assessed using the modified Total Sharp Score (mTSS)…
Abstract Number: 890 • 2018 ACR/ARHP Annual Meeting
A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib to Placebo and to Adalimumab, in Patients with Active Rheumatoid Arthritis with Inadequate Response to Methotrexate
Roy Fleischmann¹, Aileen L. Pangan², Eduardo Mysler³, Louis Bessette⁴, Charles Peterfy⁵, Patrick Durez⁶, Andrew Ostor⁷, Yihan Li², Yijie Zhou², Ahmed A. Othman², In-Ho Song⁸ and Mark C. Genovese⁹, ¹University of Texas Southwestern Medical Center at Dallas, Metroplex Clinical Research Center, Dallas, TX, ²AbbVie, Inc., North Chicago, IL, ³Organización Medica de Investigación, Buenos Aires, Argentina, ⁴Laval University, Québec, QC, Canada, ⁵Spire Sciences LLC, Boca Raton, FL, ⁶Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁷Cabrini Medical Center, Malvern, Australia, ⁸AbbVie, Inc., north chicago, IL, ⁹Stanford University Medical Center, Palo Alto, CA
Background/Purpose: To assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib (UPA), a JAK1- selective inhibitor, vs placebo (PBO) and active comparator, originator…
Abstract Number: 429 • 2017 ACR/ARHP Annual Meeting
Repair of Joint Damage Is Rare in Newly Diagnosed Rheumatoid Arthritis Patients and Appears Not to Relate to Previous Suppression of Inflammation
Joy A. van der Pol¹, Gulsah Akdemir¹, Marianne van den Broek¹, Linda Dirven¹, Pit J.S.M. Kerstens², Willem F. Lems³, Iris M. Markusse¹, Cornelia F Allaart¹ and Tom W.J. Huizinga¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ²Department of Rheumatology, Reade, Amsterdam, Netherlands, ³Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands
Background/Purpose: Joint damage in RA is thought to be irreparable. We hypothesized that in patients in whom inflammation is persistently well suppressed, repair may be…
Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting
The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Craig Scoville¹, Jessica L. Suboticki², Sheng Zhong³ and Edward C. Keystone⁴, ¹Idaho Falls Arthritis Clinic, Idaho Falls, ID, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…
Abstract Number: 1435 • 2017 ACR/ARHP Annual Meeting
Consistent Inhibition of Joint Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis: Pooled Analysis of Phase 2 and 3 Studies
Yoshiya Tanaka¹, Tsutomu Takeuchi², Satoshi Soen³, Naoki Ishiguro⁴, Hisashi Yamanaka⁵, Toshiyuki Yoneda⁶, Sakae Tanaka⁷, Takaya Nitta⁸, Naoki Okubo⁹, Harry K. Genant¹⁰ and Désirée van der Heijde¹¹, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Keio University School of Medicine, Tokyo, Japan, ³Kindai University Nara Hospital, Ikoma, Japan, ⁴Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁶Indiana University School of Medicine, Indianapolis, IN, ⁷Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Bunkyo-ku, Japan, ⁸Daiichi Sankyo Co., Ltd., Tokyo, Japan, ⁹DaiichiSankyo CO., LTD., Tokyo, Japan, ¹⁰University of California, San Francisco, CA, ¹¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that inhibits bone resorption by blocking RANKL. Phase 2 (DRIVE) and phase 3 (DESIRABLE) studies…
Abstract Number: 2909 • 2017 ACR/ARHP Annual Meeting
Only Very High Radiographic Progression Affects HAQ-DI, Results from the Swiss Scqm Cohort
Ruediger Mueller¹, Reto Thalmann², Hendrik Schulze-Koops³, Nicole Graf⁴ and Johannes von Kempis², ¹Rheumatology, MD, St. Gallen, Switzerland, ²Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ⁴Graf Biostatistics, Winterthur, Switzerland
Background/Purpose: The aim of treatment of rheumatoid arthritis is to control disease activity and to inhibit joint damage. Progression of damage is analysed by conventional…
Abstract Number: 506 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Elevations in CRP with Physical Function and Radiographic Progression over the Long-Term in Patients with Rheumatoid Arthritis
Arthur Kavanaugh¹, Boulos Haraoui², Prashanth Sunkureddi³, Benjamin Wolfe⁴, Li Wang⁴, Jessica Suboticki⁴ and Edward Keystone⁵, ¹University of California San Diego, La Jolla, CA, ²University of Montreal, Montreal, QC, Canada, ³University of Texas Medical Branch, Galveston, TX, ⁴AbbVie Inc., North Chicago, IL, ⁵Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: For patients (pts) with rheumatoid arthritis (RA), quantification of radiographic progression, through measures such as modified total Sharp score (mTSS), is not routinely captured…
Abstract Number: 578 • 2016 ACR/ARHP Annual Meeting
Do Specific Anti-Citrullinated Antibodies Predict Different Phenotype of Rheumatoid Arthritis?
Mikael Brink¹, Monika Hansson², Linda Mathsson-Alm^3,4, Johan Rönnelid⁵, Karl Skriner⁶, Guy Serre⁷, Lars Klareskog² and Solbritt Rantapää-Dahlqvist¹, ¹Rheumatology, Umeå University, Umeå, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³ThermoFisher Scientific, Uppsala, Sweden, Uppsala, Sweden, ⁴Thermo Fisher Scientific, Uppsala, Sweden, ⁵Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁶Humboldt University of Berlin, Berlin, Germany, ⁷Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France
Background/Purpose: Antibodies against cyclic citrullinated peptides (anti-CCP) have been suggested to identify a more severe phenotype of rheumatoid arthritis. In this study we have analysed…
Abstract Number: 588 • 2016 ACR/ARHP Annual Meeting
Radiographic Progression Is Less Significant in Anti-Carbamylated Antibody-Positive Patients with Rheumatoid Arthritis (RA) Who Were Clinically Active and Under the Treatment with Biological Dmards
Kazuko Shiozawa¹, Ken Tsumiyama² and Shunichi Shiozawa², ¹The Rheumatic Diseases Center, Kohnan Kakogawa Hospital, Kakogawa, Japan, ²Department of Medicine, Rheumatic Diseases Unit, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: A newly discovered anti-carbamylated protein antibody (anti-CarP) is found prior to disease-onset, associates with the conversion towards arthralgia and with a more severe disease…
Abstract Number: 926 • 2016 ACR/ARHP Annual Meeting
Increased Concentration of Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) Predate Onset of Rheumatoid Arthritis
Linda Johansson¹, Lisbeth Ärlestig¹, Heidi Kokkonen² and Solbritt Rantapaa-Dahlqvist³, ¹Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ²Public Health and Clinical Medicine/ Rheumatology, Umeå University, Umeå, Sweden, ³Umeå University, Department of Public Health and Clinical Medicine/ Rheumatology, Umeå, Sweden
Background/Purpose: Receptor activator of nuclear factor κB ligand (RANKL) an important regulator of bone metabolism has a key role in local bone destruction and osteoporosis…
Abstract Number: 2081 • 2016 ACR/ARHP Annual Meeting
Dermal Temperature Is an Excelent Prognostic Indicator to Guide RA Therapy
JoAnn Ball¹ and Maria Greenwald², ¹rheumatology, Desert Medical Advances, Palm Deseret, CA, ²Rheumatology, Desert Medical Advances, Palm Desert, CA
Background/Purpose: Nurses and rheumatology extenders can rapidly identify rheumatoid arthritis (RA) patients who flare, with high predictive value for which individual is at high risk…
Abstract Number: 2591 • 2016 ACR/ARHP Annual Meeting
Association Between Flare and Radiographic Progression in Patients with Rheumatoid Arthritis
Josef Smolen¹, Heather Jones², Ehab Mahgoub², Ronald Pedersen³ and Lisa Marshall², ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, ³Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Biologic therapy has improved RA management and enabled some patients to achieve remission. Many clinicians decrease the biologic dose for patients in low disease…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].